Improving opportunities for effective management of gastro-oesophageal reflux disease

被引:6
|
作者
Vigneri, S
Tonini, M
Scarpignato, C
Savarino, V
机构
[1] Univ Palermo, Dept Internal Med, Div Gastroenterol, I-90127 Palermo, Italy
[2] Univ Pavia, Dept Physiol & Pharmacol Sci, I-27100 Pavia, Italy
[3] Univ Parma, Lab Clin Pharmacol, Dept Internal Med, I-43100 Parma, Italy
[4] Univ Genoa, Div Gastroenterol, Dept Internal Med, Genoa, Italy
关键词
esomeprazole; gastro-oesophageal reflux disease; proton pump inhibitors;
D O I
10.1016/S1590-8658(01)80051-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The: recent introduction of proton pump inhibitors has extraordinarily improved the therapeutic approach to gastro-oesophageal reflux disease. The concept of decreasing gastric acid secretion and increasing the pH in the lower oesophagus has been demonstrated to be thera.. peutically effective and the higher the level of pH achieved, the better the results. In spite of the evident efficacy of these molecules, there ara still many patients who will continue to have symptoms despite medical treatment. Proton pump inhibitors suppress gastric acidity, but this effect shows a remarkable intel-individual variation depending on different reasons. Thus, it is still possible to optimise medical therapy for gastro-oesophageal reflux disease. Esomeprazole, the S-isomer of omeprazole, has an advantageous metabolism and this particular-feature translates into superior clinical efficacy. Clinical trials for initial and long-term treatment across the gastro-oesophageal reflux disease spectrum, have clearly demonstrated the superiority of esomeprazole over omeprazole, even if tolerability and safety are very similar.
引用
收藏
页码:720 / 730
页数:11
相关论文
共 50 条